What is Breaking?
Breaking operates at the intersection of synthetic biology and environmental engineering, focusing on the development of novel plastic degradation solutions. Originating from the Wyss Institute for Biologically Inspired Engineering at Harvard University and gestated within the ecosystem of Colossal Biosciences, the company leverages cutting-edge biological research to tackle the global plastic waste crisis. By engineering biological systems capable of breaking down synthetic polymers, Breaking is establishing itself as a leader in the sustainable materials sector, providing scalable alternatives to traditional waste management and recycling processes.
How much funding has Breaking raised?
Breaking has raised a total of $10.5M across 1 funding round:
Angel/Seed
$10.5M
Angel/Seed (2024): $10.5M, investors not publicly disclosed
Key Investors in Breaking
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Breaking?
With this major strategic investment, Breaking is poised to transition from foundational research to industrial-scale application. The company will likely prioritize the optimization of its enzymatic degradation platforms and the expansion of its laboratory infrastructure to meet the demands of enterprise-level partnerships. As the firm moves into its next phase of growth, the focus will shift toward regulatory compliance, pilot-scale testing, and the commercialization of its bio-based degradation technologies. This capital infusion provides the necessary runway to refine its synthetic biology pipeline, ensuring that the company remains at the forefront of the circular economy and sustainable biotechnology innovation.
See full Breaking company page
